Immuno-oncological treatment of Non-Small-Cell Lung Cancer (NSCLC) in advanced stage with Nivolumab

被引：0

作者：

Venturella, Fabio ^{[1
]}

Cancellieri, Giulia ^{[1
]}

Giammanco, Marco ^{[2
]}

Almerico, Anna Maria ^{[1
]}

Aleo, Igor Daniele

Liga, Anastasia Valentina ^{[1
]}

Mortillaro, Francesca ^{[1
]}

Mistretta, Irene ^{[1
]}

机构：

[1] Univ Palermo, Biol Chem & Pharmaceut Sci & Technol Dept, Palermo, Italy

[2] Univ Palermo, Surg Oncol & Stomatol Disciplines Dept, Palermo, Italy

来源：

JOURNAL OF BIOLOGICAL RESEARCH-BOLLETTINO DELLA SOCIETA ITALIANA DI BIOLOGIA SPERIMENTALE | 2023年 / 96卷 / 01期

关键词：

cancer; lung; immuno-oncology; Nivolumab; SAFETY;

D O I：

10.4081/jbr.2023.11027

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Immuno-oncology marked a therapeutic revolution in the treatment of cancer. Thanks to the new strategy that aims to awaken the immune system to fight cancer cells, there has been a change in the clinical course in the treatment of advanced Non-Small Cell Lung Cancer ( NSCLC). Our study aimed to evaluate the therapeutic efficacy of nivolumab monotherapy in the treatment of patients with advanced stage IIIB/IV non-small cell lung cancer beyond the second line. The results showed a progression-free survival of 7.35 months and an improvement in the quality of life of patients compared to other treatments. In addition, no type 3 and type 4 adverse reactions were detected in patients treated with Nivolumab. We hope that these results, already promising, will lead to an increase in overall survival in the future.

引用

下载

页数：4

共 50 条

[31] Prognostic factors of advanced stage non-small-cell lung cancer
Kwas, H.
Guermazi, E.
Khattab, A.
Hrizi, C.
Zendah, I.
Ghedira, H.
REVUE DE PNEUMOLOGIE CLINIQUE, 2017, 73 (04) : 180 - 187
[32] Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab
Freeman, A. T.
Lesperance, M.
Wai, E. S.
Croteau, N. S.
Fiorino, L.
Geller, G.
Brooks, E. G.
Poonja, Z.
Fenton, D.
Irons, S.
Ksienski, D.
CURRENT ONCOLOGY, 2020, 27 (02) : 76 - 82
[33] Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer
Ang, Yvonne L. E.
Lim, Joline S. J.
Soo, Ross A.
ONCOTARGETS AND THERAPY, 2016, 9 : 3187 - 3195
[34] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Brahmer, Julie
Reckamp, Karen L.
Baas, Paul
Crino, Lucio
Eberhardt, Wilfried E. E.
Poddubskaya, Elena
Antonia, Scott
Pluzanski, Adam
Vokes, Everett E.
Holgado, Esther
Waterhouse, David
Ready, Neal
Gainor, Justin
Aren Frontera, Osvaldo
Havel, Libor
Steins, Martin
Garassino, Marina C.
Aerts, Joachim G.
Domine, Manuel
Paz-Ares, Luis
Reck, Martin
Baudelet, Christine
Harbison, Christopher T.
Lestini, Brian
Spigel, David R.
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02): : 123 - 135
[35] THE ROLE OF CHEMOTHERAPY IN THE TREATMENT OF STAGE-III NON-SMALL-CELL LUNG-CANCER (NSCLC)
MANEGOLD, C
DRINGS, P
ONKOLOGIE, 1994, 17 (03): : 294 - 302
[36] Current status of diagnostic procedures and treatment in stage III non-small-cell lung cancer (NSCLC)
Eberhardt, Wilfried E. E.
Stuschke, Martin
Aigner, Clemens
Pogorzelski, Michael
ONKOLOGE, 2018, 24 (12): : 974 - 982
[37] Treatment Pattern in Patients with Stage III Non-Small-Cell Lung Cancer (NSCLC) in South China
Au, J. S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S308 - S308
[38] Advanced Non-Small-Cell Lung Cancer
Ren, Chuanli
Han, Chongxu
Wang, Daxin
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20): : 1998 - 1998
[39] Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer
Bersanelli, Melissa
Tiseo, Marcello
Banna, Giuseppe L.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 874 - 875
[40] Effect and biomarker of Nivolumab for non-small-cell lung cancer
Wang, Li
Zhao, Deze
Qin, Kang
Ul Rehman, Faisal
Zhang, Xiaochun
BIOMEDICINE & PHARMACOTHERAPY, 2019, 117

← 1 2 3 4 5 →